Clinical characteristics and risk of second primary lung cancer after cervical cancer: A population-based study

被引:9
作者
Qian, Chengyuan [1 ]
Liu, Hong [1 ]
Feng, Yan [1 ]
Meng, Shenglan [2 ]
Wang, Dong [1 ]
Nie, Mao [3 ]
Xu, Mingfang [1 ]
机构
[1] Army Med Univ, Daping Hosp, Canc Ctr, Chongqing, Peoples R China
[2] Army Med Univ, Daping Hosp, Dept Thorac Surg, Chongqing, Peoples R China
[3] Chongqing Med Univ, Dept Orthopaed Surg, Affiliated Hosp 2, Chongqing, Peoples R China
来源
PLOS ONE | 2020年 / 15卷 / 08期
基金
中国国家自然科学基金;
关键词
SQUAMOUS-CELL CARCINOMA; INTERNATIONAL ASSOCIATION; ADENOCARCINOMA; RADIOTHERAPY; TRENDS; MEN;
D O I
10.1371/journal.pone.0231807
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Lung cancer is increasingly common as a second primary malignancy. However, the clinical characteristics of second primary non-small cell lung cancer after cervical cancer (CC-NSCLC) compared with first primary non-small cell lung cancer (NSCLC1) is unknown. Methods The Surveillance, Epidemiology, and End Results (SEER) cancer registry between 1998 and 2010 was used to conduct a large population-based cohort analysis. The demographic and clinical characteristics, as well as prognostic data, were systematically analyzed. The overall survival (OS) in the two cohorts was further compared. The risk factors of second primary lung cancer in patients with cervical cancer were also analyzed. Results A total of 557 patients (3.52%) developed second primary lung cancer after cervical cancer, and 451 were eligible for inclusion in the final analyses. Compared with NSCLC1, patients with CC-NSCLC had a higher rate of squamous cell carcinoma (SCC) (36.59% vs 19.07%,P< 0.01). The median OS was longer for CC-NSCLC than for NSCLC1 before propensity score matching (PSM) (16 months vs. 13 months) but with no significant difference after PSM (16 months vs. 17 months). The high-risk factors for the development of cervical cancer to CC-NSCLC include age 50-79 years, black race [odds ratio (OR) 1.417; 95% confidence interval (CI) 1.095-1.834;P< 0.05], and history of radiotherapy (OR 1.392; 95% CI 1.053-1.841;P< 0.05). Conclusion Age 50-79 years, black race, and history of radiotherapy were independent risk factors for second primary lung cancer in patients with cervical cancer. Patients with CC-NSCLC had distinctive clinical characteristics and better prognosis compared with patients with NSCLC1.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study
    Meng, Yifan
    Chu, Tian
    Lin, Shitong
    Wu, Ping
    Zhi, Wenhua
    Peng, Ting
    Ding, Wencheng
    Luo, Danfeng
    Wu, Peng
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 545 - 551
  • [32] Risk of second primary cancers among patients with a first primary gastric cancer: A population-based study in North Portugal
    Morais, Samantha
    Antunes, Luis
    Bento, Maria Jose
    Lunet, Nuno
    CANCER EPIDEMIOLOGY, 2017, 50 : 85 - 91
  • [33] Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study
    Hung, Man-Hsin
    Liu, Chia-Jen
    Teng, Chung-Jen
    Hu, Yu-Wen
    Yeh, Chiu-Mei
    Chen, San-Chi
    Chien, Sheng-Hsuan
    Hung, Yi-Ping
    Shen, Cheng-Che
    Chen, Tzeng-Ji
    Tzeng, Cheng-Hwai
    Liu, Chun-Yu
    PLOS ONE, 2016, 11 (02):
  • [34] Risk of second primary lung cancer in women after radiotherapy for breast cancer
    Grantzau, Trine
    Thomsen, Mette Skovhus
    Vaeth, Michael
    Overgaard, Jens
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 (03) : 366 - 373
  • [35] Epidemiology and Survival Outcomes of Lung Cancer: A Population-Based Study
    Lin, Huan-Tang
    Liu, Fu-Chao
    Wu, Ching-Yang
    Kuo, Chang-Fu
    Lan, Wen-Ching
    Yu, Huang-Ping
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [36] Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
    Nina-Sophie Hegemann
    Anne Schlesinger-Raab
    Ute Ganswindt
    Claudia Hörl
    Stephanie E. Combs
    Dieter Hölzel
    Jürgen E. Gschwend
    Christian Stief
    Claus Belka
    Jutta Engel
    Radiation Oncology, 12
  • [37] Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study
    Marcheselli, Raffaella
    Marcheselli, Luigi
    Cortesi, Laura
    Bari, Alessia
    Cirilli, Claudia
    Pozzi, Samantha
    Ferri, Paola
    Napolitano, Martina
    Federico, Massimo
    Sacchi, Stefano
    JOURNAL OF BREAST CANCER, 2015, 18 (04) : 378 - 385
  • [38] Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
    Hegemann, Nina-Sophie
    Schlesinger-Raab, Anne
    Ganswindt, Ute
    Horl, Claudia
    Combs, Stephanie E.
    Holzel, Dieter
    Gschwend, Jurgen E.
    Stief, Christian
    Belka, Claus
    Engel, Jutta
    RADIATION ONCOLOGY, 2017, 12
  • [39] Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012
    Crocetti, Emanuele
    Mattioli, Veronica
    Buzzoni, Carlotta
    Franceschi, Silvia
    Serraino, Diego
    Vaccarella, Salvatore
    Ferretti, Stefano
    Busco, Susanna
    Fedeli, Ugo
    Varvara, Massimo
    Falcini, Fabio
    Zorzi, Manuel
    Carrozzi, Giuliano
    Mazzucco, Walter
    Gasparotti, Cinzia
    Iacovacci, Silvia
    Toffolutti, Federica
    Cavallo, Rossella
    Stracci, Fabrizio
    Russo, Antonio G.
    Caldarella, Adele
    Rosso, Stefano
    Musolino, Antonino
    Mangone, Lucia
    Casella, Claudia
    Fusco, Mario
    Tagliabue, Giovanna
    Piras, Daniela
    Tumino, Rosario
    Guarda, Linda
    Dinaro, Ylenia M.
    Piffer, Silvano
    Pinna, Pasquala
    Mazzoleni, Guido
    Fanetti, Anna C.
    Dal Maso, Luigino
    CANCER MEDICINE, 2021, 10 (19): : 6855 - 6867
  • [40] Racial and ethnic disparities in the risk of second primary malignancies in differentiated thyroid cancer patients: a population-based study
    Guo, Xingling
    He, Liang
    Xu, Haifeng
    Chen, Renjie
    Wu, Zhenyu
    Wang, Yulong
    Wu, Ying
    ENDOCRINE, 2025, 87 (03) : 1090 - 1099